Serum biomarkers at disease onset for personalized therapy in multiple sclerosisEnric Monreal, Luisa María Villar, José Ignacio Fernández-Velasco et al.|Brain|2024Cited by 44
Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy AdultsAlexander Rodero-Romero, Luisa María Villar, Enric Monreal et al.|International Journal of Molecular Sciences|2024Cited by 20
Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis PatientsRaquel Sainz-Amo, Luisa María Villar, Alexander Rodero-Romero et al.|International Journal of Molecular Sciences|2024Cited by 10
Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying TherapiesSusana Sainz de la Maza, Luisa María Villar, Lucienne Costa‐Frossard et al.|Vaccines|2023Cited by 7
Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple SclerosisEnric Monreal, Luisa María Villar, José Ignacio Fernández-Velasco et al.|International Journal of Molecular Sciences|2025Cited by 5